Literature DB >> 19578602

Tumor-induced osteomalacia: a case report.

Daniel Dutra Romualdo-Silva1, Bárbara Campolina Carvalho Silva, Cristiane Vasconcelos Caetano, Angélica Maria França Paiva Tibúrcio, Maurício Buzelin Nunes, Sérgio Almeida Pinheiro Chagas, Elizandra Tomazela Laurenti Polito, Antônio Rodrigues Ferreira, Saulo Purisch.   

Abstract

Tumor-induced osteomalacia (TIO) is a rare paraneoplasic syndrome with overproduction of fibroblast growth factor 23 as a phosphaturic agent, leading to chronic hyperphosphaturia and hypophosphatemia, associated with inappropriately normal or low levels of 1,25-dihydroxyvitamin D. Diagnosis of this disease is often challenging. The following case report described a middle-aged man with symptoms of bone pain and severe muscle weakness, who was found to have TIO. The tumor responsible for the symptoms was localized on his thigh and its resection resulted in normalization of blood chemistry and complaints. Subsequent microscopic examination revealed a phosphaturic mesenchymal tumor, mixed connective tissue type. The authors reinforce the importance of recognition of this disease, as severe disability and even death can be avoided with the surgical removal of the causative tumor.

Entities:  

Mesh:

Year:  2009        PMID: 19578602     DOI: 10.1590/s0004-27302009000300014

Source DB:  PubMed          Journal:  Arq Bras Endocrinol Metabol        ISSN: 0004-2730


  3 in total

Review 1.  Tumor-induced osteomalacia.

Authors:  William H Chong; Alfredo A Molinolo; Clara C Chen; Michael T Collins
Journal:  Endocr Relat Cancer       Date:  2011-06-08       Impact factor: 5.678

2.  'Tumour-induced osteomalacia'.

Authors:  Javier Munoz; Rosa Michel Ortega; Florence Celzo; Vijayalakshmi Donthireddy
Journal:  BMJ Case Rep       Date:  2012-06-25

3.  Tumor-induced osteomalacia: experience from a South American academic center.

Authors:  G González; R Baudrand; M F Sepúlveda; N Vucetich; F J Guarda; P Villanueva; O Contreras; A Villa; F Salech; L Toro; L Michea; P Florenzano
Journal:  Osteoporos Int       Date:  2017-03-25       Impact factor: 4.507

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.